Risk factors of postictal generalized EEG suppression in generalized convulsive seizures

Veriano Alexandre1, Blanca Mercedes1, Luc Valton1

  • 1From the Department of Functional Neurology and Epileptology (V.A., B.M., S.R.) and the Institute of Epilepsies (E.H., P.R., S.R.), Hospices Civils de Lyon and Lyon 1 University; Lyon's Neuroscience Research Center (V.A., B.M., P.R., S.R.), INSERM U1028/CNRS UMR 5292, Lyon, France; the Hospital of Clinics of Ribeirão Preto (V.A.), University of São Paulo, Brazil; the Department of Neurology (L.V., M.D.), University Hospital of Toulouse; the Neurology Department (L.M., J.J.), University Hospital of Nancy; the Clinical Neurophysiology and Epileptology Department (F.B.), Timone Hospital, Marseille; the Department of Clinical Neurophysiology (W.S.), Lille University Medical Center, EA 1046, University of Lille2; the Department of Neurology (E.H.), University Hospital of Strasbourg; the Department of Neurology (C.M.), Hôpital Pellegrin, Bordeaux; the Epilepsy Unit (F.C.), Department of Neurosurgery, Centre Hospitalier Sainte-Anne; University Paris Descartes; La Teppe Epilepsy Center (J.P.), Tain l'Hermitage; the Epilepsy Unit (A.C.), Montpellier; the Department of Neurology (A.N.), University Hospital of Rennes; the Epileptology Unit (V.N.), Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière and Brain and Spine Institute (ICM; INSERM UMRS1127, CNRS UMR7225, UPMC University Paris 06), Paris; the Department of Neurology (P.K.), Michallon Hospital, GIN, INSERM U836, UJF, Grenoble Alpes University, Grenoble; the Department of Clinical Neurophysiology (B.D.T.), INSERM U930, University Hospital of Tours; the Department of Neurology (P.T.), University Hospital of Nice; the Department of Neurology (S.R.), University Hospital of Clermont-Ferrand, France; and the Department of Clinical Neurosciences (P.R.), Centre Hospitalo-Universitaire Vaudois, Lausanne, Switzerland.

Neurology
|September 4, 2015
PubMed
Abstract

Related Concept Videos

Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.2K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.1K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
969
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.7K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.2K